1. 2-Difluoromethylornithine totally prevented any increases in putrescine and spermidine concentrations in the ventral prostate of castrated rats during a 6-day testosterone treatment. Prostatic ornithine decarboxylase activity was inhibited by 80%, whereas S-adenosylmethionine decarboxylase was stimulated by more than 9-fold. 2. In seminal vesicle, the inhibition of putrescine and spermidine accumulation, as well as ofornithine decarboxylase activity, was only minimal, and no stimulation of S-adenosylmethionine decarboxylase was observed. 3. Administration of methylglyoxal bis(guanylhydrazone) to castrated androgen-treated rats resulted in a marked increase in concentrations of all prostatic polyamines. Prostatic ornithine decarboxylase activity was nearly 2 times and adenosylmethionine decarboxylase activity 9 times higher than that of the testosterone-treated animals. 4. In contrast with ventral prostate, methylglyoxal bis(guanylhydrazone) treatment inhibited moderately the accumulation of spermidine and spermine in seminal vesicle, although both ornithine decarboxylase and S-adenosylmethionine decarboxylase activities were stimulated. 5. Difluoromethylornithine inhibited significantly the weight gain of ventral prostate, but methylglyoxal bis(guanylhydrazone) produced a substantial increase in prostatic weight. These changes were largely due to the fact that the volume of prostatic secretion was greatly decreased by difluoromethylornithine, whereas methylglyoxal bis(guanylhydrazone) increased the amount of secretion. 6. Treatment with difluoromethylornithine strikingly increased the methylglyoxal bis(guanylhydrazone) content of both ventral prostate and seminal vesicle, but even under these conditions the drug concentration remained low in comparison with other tissues. 7. The results indicate that a combined use of these two polyamine anti-metabolites does not necessarily result in a synergistic growth inhibition of the androgen-induced growth of male accessory sexual glands.
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Difluoromethylornithine is a specific inhibitor of putrescine and spermidine biosynthesis in both cell cultures and animal tissues (for references see Heby & Janne, 1981) , and it has the apparent advantage of being well tolerated by experimental animals. Another inhibitor of polyamine synthesis, methylglyoxal bis(guanylhydrazone), has been widely used in combination with difluoromethylornithine. The rationale of this combination is based on the fact that a prior treatment with difluoromethylornithine greatly enhances the uptake of methylglyoxal bis(guanylhydrazone) (AlhonenHongisto et al., 1980) . This drug combination exerts a distinct cytotoxic effect on cultured cells, transplanted tumours, hyperproliferative mouse skin and in human leukaemia (Seppanen et al., 1981a,b; Siimes et al., 1981; Kapyaho et al., 1983) .
Ventral prostate of the rat contains exceptionally high concentrations of spermidine and spermine (Pegg et al., 1970; Danzin et al., 1982) , which are also components of the prostatic secretion (Mann & Lutwak-Mann, 1981) . Castration results in a swift involution of male reproductive glands, and this effect can be reversed by testosterone administration. Among the first responses to the androgen is the stimulation of enzymes catalysing the synthesis of the polyamines (Pegg et al., 1970; Piik et al., 1977; Kapyaho et al., 1980) . Prostatic
Vol. 219 ornithine decarboxylase activity appears to be extremely sensitive to inhibition by difluoromethylornithine (Danzin et al., 1979a,b) , and this compound also inhibits moderately the growth of ventral prostate of developing young rats (Danzin et al., 1982) or of castrated rats treated with testosterone (Danzin et al., 1979b (Danzin et al., 1979b) .
The concept of the combined use of difluoromethylornithine and methylglyoxal bis(guanylhydrazone) for growth inhibition has also been applied in prostatic neoplasia. Growth of prostatic cancer cells transplanted subcutaneously in rats was inhibited by combined treatment with these two polyamine anti-metabolites (Dunzendorfer et al., 1983; Herr & Kleinert, 1983 for 20min in the cold. The enzyme activities and the content of difluoromethylornithine were assayed in the supernatant fraction. The other half of the tissues was homogenized in 0.2M-HC104, and centrifuged at 2000g for 5min. Polyamines and methylglyoxal bis(guanylhydrazone) were determined in the supernatant fractions, and the pellet was used for the determination of DNA content.
Isolation of the prostatic secretion
The thin capsule surrounding the ventral prostatic lobes was removed, and the tissue was cut into pieces. The pieces were placed on a grid, which was mounted inside a centrifuge tube. The tubes were centrifuged at 3000g for 10min in the cold.
During the centrifugation the secretion was squeezed to the bottom of the tube, which contained 0.1 ml of 25 mM-Tris/HCI buffer, pH 7.2, with 0.1 mM-EDTA and 5 mM-dithiothreitol. The volume of the secretion was measured and it was divided into two parts, one for enzyme and difluoromethylornithine assays and the other for the determination of polyamine, methylglyoxal bis(guanylhydrazone), DNA and protein contents.
Analytical methods
Ornithine decarboxylase activity was assayed by the method of Janne & Williams-Ashman (1971a) and S-adenosylmethionine decarboxylase as described by Janne & Williams-Ashman (1971b) . Polyamines were determined as their dansylated derivatives by the method of Seiler (1970) as modified by Dreyfuss et al. (1973) . Methylglyoxal bis(guanylhydrazone) was assayed in neutralized HCIO4 supernatants by the method of . Protein was determined by the method of Lowry et al. (1951) , with bovine serum albumin as the standard, and DNA was determined after hot-trichloroacetic acid hydrolysis by the method of Giles & Myers (1965) , with deoxyguanosine as the standard. Enzymic determination of difluoromethylornithine
The determination of difluoromethylornithine was based on its ability to inhibit irreversibly ornithine decarboxylase activity. To obtain the enzyme preparation, Wistar rats were injected intraperitoneallywiththioacetamide (150mg/kg body wt.) to induce the hepatic ornithine decarboxylase activity. The animals were decapitated 20h later, and their livers were removed and homogenized in 25mM-Tris/HCl buffer, pH7.2, containing 0.1 mM-EDTA and 5 mM-dithiothreitol. The homogenate was centrifuged at 100 000g for 20min, and the supernatant fraction was used as source of the enzyme. A portion of the tissue extract containing difluoromethylornithine was evaporated to dryness in a hot-water bath to inactivate endogenous. ornithine decarboxylase, and the residue was dissolved in 25mM-Tris/HCl, pH7.2, containing 0.2mM-EDTA. Then 1254ul of the enzyme preparation, 50,l of the difluoromethylornithine-containing sample and 45pl of a mixture containing 22mM-EDTA, 22mM-dithiothreitol and 2.2mM-pyridoxal phosphate in 0.55M-Tris/HCl buffer, pH 7.2, were incubated for 20min at 37°C to allow the reaction between difluoromethylornithine and ornithine decarboxylase. Thereafter lOp of 25mM-L-oMithine and 204u1 of DL-[1-14C]ornithine (0.8yCi) were added, which effectively stops any further enzyme inhibition, and the residual ornithine decarboxylase activity was determined as described by Janne & WilliamsAshman (1971a) . The concentration of difluoromethylornithine in the tissue samples was calculated with the aid of a standard curve run in parallel by plotting log (1/enzyme activity) against the concentration of difluoromethylornithine.
Results Accumulation ofpolyamines in ventral prostates and seminal vesicles during androgen-induced growth Treatment with difluoromethylornithine totally prevented the accumulation of putrescine and spermidine in the ventral prostate of castrated testosterone-treated rats, and even the accumulation of spermine was inhibited by 64% (Table 1) .
In contrast, treatment with methylglyoxal bis-(guanylhydrazone) produced a paradoxical increase in the concentrations of all three polyamines (Table 1) . When both treatments were combined, the concentration of spermidine remained low, although spermine was substantially higher than in response to difluoromethylornithine alone (Table  1) .
The effects were much less pronounced in seminal vesicle. Difluoromethylornithine decreased moderately the contents of putrescine and spermidine, whereas methylglyoxal bis(guanylhydrazone) treatment resulted in a distinct decrease in spermidine (and spermine) concentrations (Table 2 ). The combined treatment did not result in any appreciable potentiation of the drug effects, with the possible exception of a further decrease in spermine content (Table 2) . Table 1 . Effects ofdifluoromethylornithine, methylglyoxal bis(guanylhydrazone) and their combination on polyamine accumulation in the ventral prostate of castrated rats treated with testosterone Castrated rats received daily injections of testosterone propionate (2.5 mg/animal subcutaneously in olive oil).
Difluoromethylornithine was given in drinking water (30g/1), starting 6h before the first testosterone injection, and methylglyoxal bis(guanylhydrazone) was given as daily intraperitoneal injections (25mg/kg) concomitantly with testosterone. After 6 days' treatment, the animals were decapitated and polyamines were determined as described in the Experimental section. The results represent means + S.E.M. for five animals in each group. Abbreviations used: DFMO, difluoromethylornithine; MGBG, methylglyoxal bis(guanylhydrazone); n.d., not detectable. *P < 0.01 and **P<0.001, in comparison with testosterone-treated group. Table 3 , ornithine decarboxylase activity was only partially inhibited by difluoromethylornithine in both tissues. Difluoromethylornithine strikingly (10-fold) increased the activity of adenosylmethionine decarboxylase in ventral prostate, but the drug had no effect on the enzyme activity in seminal vesicle (Table 3 ). The stabilization of adenosylmethionine decarboxylase by methylglyoxal bis(guanylhydrazone) was reflected by a 10-fold stimulation of the enzyme activity in both tissues (Table 3) . Methylglyoxal bis(guanylhydrazone) also doubled the activity of ornithine decarboxylase in both tissues (Table 3 ). The combination of the two drugs produced additive stimulation of adenosylmethionine decarboxylase activity in ventral prostate. Although difluoromethylornithine did not stimulate adenosylmethionine decarboxylase activity in seminal vesicle, the combined treatment further enhanced the enzyme activity in comparison with methylglyoxal bis(guanylhydrazone) alone (Table 3) .
The activities of both ornithine decarboxylase and adenosylmethionine decarboxylase in ventral prostatic secretion reflected the activities of the tissue. Only traces of ornithine decarboxylase activity were found in the secretion, whereas the activity of adenosylmethionine decarboxylase represented 10% of that found in prostate (results not shown). This may indicate better stability of adenosylmethionine decarboxylase towards proteolytic enzymes present in the secretory fluid.
Effects ofdifluoromethylornithine and methylglyoxal bis(guanylhydrazone) on the testosterone-induced growth of ventral prostate and seminal vesicle Treatment of castrated rats with testosterone propionate for 6 days increased the weight of the ventral prostate and seminal vesicles 5-fold and 4-fold respectively (Table 4) . Difluoromethylornithine alone significantly inhibited the androgeninduced weight gain of ventral prostate, whereas methylglyoxal bis(guanylhydrazone) produced an opposite effect: the prostatic weight was further increased by 34% (Table 4) . During combined treatment, the weight of ventral prostate increased as in the animals receiving testosterone alone. Neither drug, alone or in combination, had any significant effect on the growth of seminal vesicles (Table 4) .
Effect ofpolyamine anti-metabolites on the secretory activity of ventral prostate Table 5 shows that a treatment with difluoromethylornithine effectively prevented the develop-ment of the prostatic secretory function. Both the volume of the secretion and the concentration of protein secreted were only about 20% of that of the androgen-treated controls. In striking contrast, methylglyoxal bis(guanylhydrazone) treatment resulted in an enhanced production of prostatic fluid, whereas the concentrations of protein and polyamines secreted were not significantly increased (Table 5 ). The increased secretion volume of prostates from animals treated with both drugs reflected the effect of methylglyoxal bis(guanylhydrazone) rather than that of difluoromethylornithine (Table 5 ). However, the concentrations of secreted spermidine remained low even during the combined treatment. Concentrations of difluoromethylornithine and methylglyoxal bis(guanylhydrazone) in male accessory sexual glands and other tissues in testosterone-treated castrated rats Table 6 shows that intraperitoneal injections of methylglyoxal bis(guanylhydrazone) resulted in the highest tissue concentration of the drug in liver. The drug concentrations in kidney and small intestine were about half of that found in liver, whereas the content of methylglyoxal bis(guanylhydrazone) in ventral prostate and seminal vesicle remained very low (about one-tenth of the liver concentration) (Table 6 ). Concomitant treatment with difluoromethylornithine only slightly enhanced the accumulation of methylglyoxal bis-(guanylhydrazone) in liver, kidney and small intestine, but it produced a strikingly enhanced drug accumulation in ventral prostate (7-fold) and seminal vesicle (3-fold) (Table 6) . However, even then the methylglyoxal bis(guanylhydrazone) cJoncentrations remained lower than in the other tissues. Methylglyoxal bis(guanylhydrazone) treatment appeared to have no effect on the concentration of difluoromethylornithine, as shown in Table  7 . Further, when the rather large statistical Table 5 . Effects of difluoromethylornithine, methylglyoxal bis(guanylhydrazone) and their combination on the secretory activity of ventral prostate of castrated rats treated with testosterone The separation of the prostatic secretion and the determination of proteins and polyamines are described in the Experimental section. Percentages in parentheses are percentages of those for the respective testosterone-treated group. The prostates of castrated control rats contained no secretion. Further, polyamine content of the testosterone + DFMO-treated group could not be estimated because of the small amount of the prostatic secretion. For other experimental details see the legend for Vol. 219 variation within each experimental group is considered, the molar concentration of difluoromethylornithine in prostatic tissue and secretion showed little difference. This was in distinct contrast with methylglyoxal bis(guanylhydrazone), which was preferably accumulated in the prostatic tissue as compared with the secretion (Table 7) .
Discussion
Methylglyoxal bis(guanylhydrazone) has been used clinically as an anti-cancer drug in the early sixties (Regelson & Holland, 1961; Mihich, i963) . Although experimental evidence suggested that the mechanism of action of the drug was possibly linked to the metabolism of spermidine (Mihich, 1963) , it was not until 1972 that Williams-Ashman & Schenone discovered that methylglyoxal bis-(guanylhydrazone) is an extremely potent inhibitor of eukaryotic adenosylmethionine decarboxylase and hence inhibits the synthesis of spermidine and spermine.
Methylglyoxal bis(guanylhydrazone) apparently utilizes the cellular carrier system designed for natural polyamines for its transport into cells (Dave & Caballes, 1973; Seppiinen et al., 1980) . This fact, combined with the finding that polyamine depletion produced by inhibitors of ornithine decarboxylase, most notably by difluoromethylornithine, greatly enhances the uptake of polyamines offered the rationale for a sequential combination of these two drugs (Seppanen et al., 198 la, b) . The cytotoxicity exerted by the combination appears to show some tumour selectivity as regards the tissue distribution of methylglyoxal bis(guanylhydrazone) after a prior treatment with difluoromethylornithine (Seppanen et al., 1983) .
The view that difluoromethylornithine selectively stimulates the putative polyamine carrier in tumour tissues has been supported by findings of Chaney et al. (1983) showing that EMT6 tumours transplanted in mice took up most effectively, in comparison with host tissues, labelled putrescine in response to a prior difluoromethylornithine treatment.
Androgen-induced growth of prostatic tissue of castrated rodents is a useful model for studies with polyamine anti-metabolites, since this organ not only contains high concentrations of polyamines but also secretes large amounts of these compounds. Furthermore, the involution as well as the regrowth of this organ is accompanied by striking changes in polyamine synthesis and accumulation (Pegg et al., 1970; Piik et al., 1977) .
By preventing the accumulation of putrescine and spermidine with injections of difluoromethylornithine during testosterone treatment of castrated rats, Danzin et al. (1979b) concluded that polyamines are involved in the maintenance of functional secretory epithelium. Our present results also point in this direction, as the volume of prostatic secretion was radically decreased in response to difluoromethylornithine treatment (Table 5 ). In distinct contrast with this treatment, daily injections of methylglyoxal bis(guanylhydrazone) resulted in a more than 2-fold increase in the volume of prostatic secretion (Table 5 ). Whether this is related to the peculiar rise in the tissue polyamine concentrations after treatment with methylglyoxal bis(guanylhydrazone) ( Table 1) , or whether the latter drug can mimic the possible action of polyamines on prostatic secretory function, is not known. In fact, the finding ( Table 1) that combined treatment with the two drugs decreased prostatic polyamines to the concentration found after difluoromethylornithine alone, yet the volume of prostatic secretion did not decrease (Table 5) , may even support the view that methylglyoxal bis(guanylhydrazone) directly stimulates the secretory function of the gland.
Polyamine accumulation in rat ventral prostate appears to be extremely sensitive to difluoromethylornithine, whereas that in seminal vesicle is remarkably insensitive in this respect. The opposite is true for methylglyoxal bis(guanylhydrazone): in ventral prostate this drug paradoxically enhanced the accumulation of all three polyamines (Table 1) , whereas in seminal vesicle the concentrations of all three polyamines decreased in response to the treatment with the drug (Table 2) . One may try to find some kind of explanation for these phenomena in the different enzyme patterns of the two sexual accessory organs. In ventral prostate the androgen-induced accumulation of polyamines apparently relies on the striking (almost 500-fold) stimulation of ornithine decarboxylase activity, which was about 3 times higher than the maximally stimulated activity of adenosylmethionine decarboxylase (Table 3) . In seminal vesicle, the activities of the two decarboxylases were stimulated exactly to the same extent (Table  3 ). The possibility that the differences would result from different tissue drug concentrations remains open, since ventral prostate accumulated difluoromethylornithine more effectively than did seminal vesicles (Table 7) .
Although the concentration of methylglyoxal bis(guanylhydrazone) in the accessory sexual glands of testosterone-treated castrated rats was by far the lowest of all tissues analysed (Table 6) , treatment with difluoromethylornithine produced the most striking stimulation of the drug's accumulation in prostate (7-fold) and seminal vesicle (3-fold) ( Table 6 ). The latter observation is in good agreement with the report by Kadmon et al. (1982) demonstrating that prostatic putrescine uptake was enhanced by more than 10-fold when castrated rats were treated with a combination of testosterone and difluoromethylornithine.
Even though testosterone-induced growth of rat ventral prostate and seminal vesicle appears to respond poorly to the antiproliferative action of polyamine anti-metabolities (with the possible exception of difluoromethylornithine-induced diminution of prostatic secretion), a few reports indicate that experimental tumours of prostatic origin may be especially sensitive to the combined action of difluoromethylornithine and methylglyoxal bis(guanylhydrazone) when transplanted subcutaneously (Dunzendorfer et al., 1983; Herr & Kleinert, 1983) . Of special interest is the report by Herr & Kleinert (1983) showing that the toxicity of methylglyoxal bis(guanylhydrazone) can be dramatically decreased, without lowering the dose, by combining the drug with difluoromethylornithine.
